Catalent (NYSE:CTLT) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a research note issued to investors on Friday morning. The firm issued a sell rating on the stock.

Other equities analysts have also recently issued research reports about the company. Royal Bank of Canada reiterated a sector perform rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, February 20th. Stephens restated an equal weight rating and set a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Barclays raised their target price on Catalent from $45.00 to $47.00 and gave the stock an equal weight rating in a report on Thursday, January 25th. Finally, UBS Group reaffirmed a neutral rating and set a $63.50 price target (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of Hold and an average target price of $52.46.

Catalent Price Performance

Shares of CTLT stock opened at $55.48 on Friday. The stock’s fifty day moving average is $56.81 and its 200-day moving average is $48.24. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. The stock has a market capitalization of $10.04 billion, a PE ratio of -8.16, a PEG ratio of 6.04 and a beta of 1.20. Catalent has a 52 week low of $31.45 and a 52 week high of $60.20.

Catalent (NYSE:CTLT) last announced its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. Catalent’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.62 EPS. Equities research analysts expect that Catalent will post 0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Catalent

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Cetera Advisor Networks LLC raised its position in Catalent by 7.1% in the 1st quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock valued at $217,000 after buying an additional 130 shares during the last quarter. Mackay Shields LLC grew its stake in Catalent by 0.6% in the first quarter. Mackay Shields LLC now owns 25,749 shares of the company’s stock valued at $2,856,000 after purchasing an additional 149 shares in the last quarter. Czech National Bank grew its stake in Catalent by 0.7% in the first quarter. Czech National Bank now owns 31,801 shares of the company’s stock valued at $1,795,000 after purchasing an additional 228 shares in the last quarter. Wetherby Asset Management Inc. grew its stake in Catalent by 5.1% in the first quarter. Wetherby Asset Management Inc. now owns 5,023 shares of the company’s stock valued at $557,000 after purchasing an additional 243 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV grew its stake in Catalent by 1.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 21,164 shares of the company’s stock valued at $953,000 after purchasing an additional 252 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.